Hims House Ep 12 - Hims & Hers Q3 Earnings Recap (Nov 6, 2024)
11 snips
Nov 6, 2024 Delve into the exciting financial landscape of Hims & Hers Health as they celebrate surpassing 2 million subscribers. The discussion spotlights the booming interest in personalized solutions and the anticipated launch of liraglutide for weight management. Key financial metrics reveal impressive growth, raising eyebrows amidst market skepticism. Explore the evolving role of multi-product strategies and the potential for meal replacements, all while navigating the intricate trends of personalized medicine and consumer engagement.
AI Snips
Chapters
Transcript
Episode notes
Liraglutide vs. Semaglutide/Tirzepatide
- Liraglutide, while effective for diabetes and weight management, isn't as effective as Semaglutide or Tirzepatide.
- Its side effect profile is similar, but some tolerate it less well, and it requires daily injections.
Personalized GLP-1s
- HIMS & HERS plans to offer Semaglutide and Tirzepatide via personalized plans after shortages end.
- Over 50% of customers now use personalized products, potentially reaching 75-80%.
Personalized Medicine & Cash Flow
- Personalized medicine increases cash flow stickiness by tailoring treatment to individual patients.
- This stickiness enhances long-term shareholder value by generating more consistent cash flow.